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Abstract 
The radiological features of intracranial haemorrhage are well described in the literature, 
but atypical appearances can sometimes develop. We report a case of chemotherapy-
induced thrombocytopenia resulting in fatal intracranial haemorrhage in a man 
undergoing autologous peripheral stem cell transplantation. The CT showed an unusual 
appearance, with separation of blood products and fluid within the haemorrhage leading 
to a wine-glass-shaped outline in the image. This case draws attention to this uncommon 
radiological finding and emphasises the risks of allosensitisation following 
chemotherapy and peripheral stem cell transplantation. 
 
Case Report 
A 39-year-old male received high-dose chemotherapy (intravenous etoposide, carboplatin and 
ifosfamide) for recurrent testicular teratoma, and subsequently underwent autologous peripheral stem 
cell transplantation. One week after the procedure, the patient had developed renal tubular failure 
believed to be secondary to the high-dose carboplatin, with therapy-resistant hypertension (190/120 
mm Hg) and a serum creatinine of 697 mmol/l. Therefore emergency haemodialysis was performed. In 
addition, there had been an immune response to donor platelets resulting in thrombocytopenia with 
platelet counts of 3,000/μl. This led to a search for HLA-matched platelets to attempt to maintain the 
count above 10,000/μl. However, identical or closely HLA-matched blood products for this patient were 
not obtainable.   
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One week later, shortly after a session of haemodialysis, he developed a severe headache and 
progressive drowsiness. An urgent CT scan of the brain (fig. 1) demonstrated an intracerebral bleed in 
the right hemisphere, subarachnoid haemorrhage around the basal cisterns and compression of the 
right ventricle with midline shift. The intracerebral bleed was layered in appearance due to red cell 
sedimentation as the platelet count of 3,000/μl at the time of the event was inadequate for clot formation 
and retraction, and the subarachnoid bleed surrounding the midbrain created an unusual ‘wine glass’ 
appearance. This catastrophic haemorrhage was probably due to thrombocytopenia, exacerbated by 
hypertension and the heparin used during haemodialysis. The patient was ventilated, but died before 
surgical intervention was possible. 
Discussion 
There are few large-scale reports into thrombocytopenia following chemotherapy for 
solid tumours, leading to variability in clinical practice [1]. In general, guidelines are 
extrapolated from available data in haematological malignancies [2] and the threshold of 
20,000 platelets/μl before administration of prophylactic platelet transfusions is widely 
used [2]. Recent studies in solid tumours suggest that this threshold may be acceptable, as 
the incidence of chemotherapy-induced thrombocytopenia remains low and at-risk 
patients are readily identifiable [3]. Moreover, the efficacy of such transfusions is 
reportedly limited [3], as seen in our patient. For patients who are refractory to platelet 
transfusions, HLA alloimmunisation is the commonest cause, and HLA-matched platelets 
have been shown to improve platelet increments when transfused, compared with 
unmatched platelets [4]. Unfortunately, no appropriate match was available for this case. 
Even when significant thrombocytopenia occurs, the incidence of severe events such as 
intracranial haemorrhage is low [3, 5], and major bleeding is associated with, among 
other factors, a platelet count of less than 10,000/μl [6]. The risks of intracranial 
haemorrhage are, however, not insignificant, particularly in the presence of other risk 
factors, and the outcome is often devastating, and mortality rates very high [7]. 
The radiological appearance of intracranial haemorrhages differs, depending on the 
timing of the imaging after the event, due to differences in composition of the blood 
breakdown products [8]. The earliest phase (up to 12 h after the haemorrhage) is referred 
to as the ‘hyperacute stage’ and the CT appearance is usually hyperdense. During this 
stage, the bleed is usually comprised of a liquid collection of intracellular oxygenated 
haemoglobin, and in the presence of adequate platelet function, this will gradually clot 
over the following hours, and retract, expelling serum and creating vasogenic oedema in 
the surrounding brain tissue [9]. CT imaging of our patient was performed 6 h after the 
devastating haemorrhage (i.e. in the hyperacute stage), and we noted an unusual layering 
effect, with the formation of a fluid-blood level within the haemorrhage and unclotted 
blood settling within the dependent portion of the ventricular or subarachnoid space. 
Additionally, there was significant background low attenuation observed in the right 
hemisphere, and this may have represented haemorrhage within the infarct, possibly 
related to the uncontrolled hypertension. Whilst it has been reported that 
thrombocytopenia alone may not alter the distinctive CT appearances of intracranial 
haemorrhage [10, 11], there were other mitigating factors in this case; not least the use of 
heparin during the preceding haemodialysis session. This may have contributed further to 
the impaired blood clotting and resulted in the atypical radiological appearance. Thus a 
pattern comparable to a wine glass outline was created, and to our knowledge, this has not 
been previously described in such a context.  
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This case highlights the risks associated with allosensitisation following chemotherapy 
and peripheral stem cell transplantation. The profound effects of the impaired clotting in 
the setting of acute renal failure requiring haemodialysis, and the subsequent intracranial 
haemorrhage, emphasises the difficulties with managing complex co-existing medical 
complications of chemotherapy. Thus we report this rare radiological finding as a 
consequence of these complications. 
 
 
 
 
 
 
Fig. 1. An axial unenhanced CT image from a 39-year-old male with severe intracranial haemorrhage. 
The CT demonstrates a gross intracerebral haematoma in the parieto-occipital region of the right 
cerebral hemisphere. The layering effect seen in the haematoma suggests impaired clotting, with 
multiple levels noted. There is also evidence of intraventricular haemorrhage in the left lateral ventricle 
and subarachnoid haemorrhage around the basal cisterns. A gross midline shift with mass effect of the 
right cerebral hemisphere can be seen. 
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